Solid Biosciences (SLDB) Downgraded by Goldman Sachs Group to Sell

Goldman Sachs Group downgraded shares of Solid Biosciences (NASDAQ:SLDB) from a neutral rating to a sell rating in a research report released on Tuesday, Briefing.com Automated Import reports. The brokerage currently has $4.00 price target on the stock, down from their previous price target of $5.00.

A number of other research analysts also recently weighed in on SLDB. Chardan Capital reaffirmed a buy rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Thursday, February 7th. Leerink Swann downgraded shares of Solid Biosciences from an outperform rating to a market perform rating in a research report on Thursday, February 7th. Citigroup raised shares of Solid Biosciences from a sell rating to a neutral rating and set a $8.00 target price for the company in a research report on Friday, February 8th. Svb Leerink downgraded shares of Solid Biosciences from an outperform rating to a market perform rating in a research report on Friday, February 8th. Finally, Zacks Investment Research raised shares of Solid Biosciences from a hold rating to a buy rating and set a $8.25 target price for the company in a research report on Wednesday, February 13th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $20.11.

Shares of SLDB stock traded down $0.13 during trading hours on Tuesday, hitting $6.05. 825 shares of the company were exchanged, compared to its average volume of 556,802. The company has a quick ratio of 10.31, a current ratio of 6.99 and a debt-to-equity ratio of 0.07. Solid Biosciences has a 52 week low of $5.23 and a 52 week high of $54.84. The company has a market capitalization of $209.25 million, a price-to-earnings ratio of -2.71 and a beta of 1.68.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.22). On average, equities analysts expect that Solid Biosciences will post -2.53 EPS for the current year.

In other news, major shareholder Boxer Capital, Llc sold 450,000 shares of Solid Biosciences stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $9.88, for a total value of $4,446,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Juan Andrey Zarur sold 8,000 shares of Solid Biosciences stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $10.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. Company insiders own 31.20% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Flinton Capital Management LLC acquired a new stake in shares of Solid Biosciences during the 4th quarter worth about $47,000. Legal & General Group Plc lifted its stake in shares of Solid Biosciences by 47.8% during the 3rd quarter. Legal & General Group Plc now owns 1,825 shares of the company’s stock worth $86,000 after buying an additional 590 shares during the last quarter. First Manhattan Co. lifted its stake in shares of Solid Biosciences by 100.0% during the 4th quarter. First Manhattan Co. now owns 2,000 shares of the company’s stock worth $53,000 after buying an additional 1,000 shares during the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of Solid Biosciences during the 4th quarter worth about $83,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in shares of Solid Biosciences by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 4,160 shares of the company’s stock worth $111,000 after buying an additional 3,249 shares during the last quarter. 63.39% of the stock is owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Further Reading: What is an overbought condition?

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.